Quoin Pharmaceuticals Ltd. — Form 8-K
Filed September 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Quoin Pharmaceuticals announced FDA granted Rare Pediatric Disease (RPD) Designation for QRX003 in Peeling Skin Syndrome (PSS) on September 8, 2026. This is the second RPD designation for QRX003 (first was Netherton Syndrome). Upon NDA approval, Quoin may receive a freely tradable Priority Review Voucher (PRV). The company plans to initiate a Phase 2 study enrolling up to 12 pediatric and adult PSS patients in the U.S. and Europe before end of 2026; PSS currently has no approved treatments.
Why this rating
RPD designation and potential PRV are meaningful for a $5.4M-cap company—PRVs valued $80M–$120M historically. Second indication expands pipeline. Near-term risk: small trial size, binary clinical/regulatory outcomes.
Price action (we called it positive)
before filing · preread $6.90 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.